Quantcast
Last updated on April 18, 2014 at 12:36 EDT

Latest Sciele Pharma Stories

2008-09-17 12:00:35

Sciele Pharma, which specializes in sales, marketing and development of branded prescription products, has completed a pivotal Phase III program to support an NDA filing for glycopyrrolate liquid. The company completed its open-label, 24-week, multi-center study to assess the safety of oral glycopyrrolate liquid for the treatment of chronic, moderate-to-severe drooling in pediatric patients three to 18 years of age. Administration of the glycopyrrolate liquid was found to be well-tolerated...

2008-09-11 12:00:43

Sciele Pharma and Addrenex Pharmaceuticals have announced that the preliminary analysis of the Phase III clinical study investigating the use of Clonicel for the treatment of attention deficit hyperactivity disorder has shown statistically significant improvement over placebo. The study has indicated that Clonicel achieved statistical significance on the primary endpoint, which is based on the attention deficit hyperactivity disorder (ADHD) rating scale of 18 symptoms developed by the...

2008-07-17 12:01:18

Sciele Pharma, which develops branded prescription products, has announced that the FDA has issued an approvable letter for the head lice treatment. Sciele Pharma is working closely with Summers Laboratories and the FDA to provide additional information that was requested.

2008-07-01 18:00:29

DURHAM, N.C., July 1 /PRNewswire/ -- Two years after Addrenex Pharmaceuticals set it sights on building a new class of drugs to regulate "adrenergic excess," the small Durham company has signed its second major deal with Sciele Pharma, this time to co-develop a new compound for hypertension and other potential indications. Adrenalin is well known as the hormone that triggers the "fight or flight" reaction in response stress or danger. But Addrenex scientists recognized this hormone, and...